Patents by Inventor Michal Caspi Tal

Michal Caspi Tal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230391857
    Abstract: The CD47 mimic protein of Borrelia burgdorferi is identified as p66 protein. Blocking the p66 protein on the pathogen Improves the immune response of an infected individual, and allows a more complete and/or more rapid resolution of Borrelia infection. The disclosure provides a method of inhibiting or treating an infection by a Borrelia pathogen, the method comprising administering an effective amount of an anti-p66 agent that reduces binding of p66 on the pathogen to signal regulatory protein a (SIRPa) on a phagocytic cell, where the agent (i) specifically binds to p66, or (ii) is a p66 polypeptide or derivative thereof.
    Type: Application
    Filed: October 29, 2021
    Publication date: December 7, 2023
    Inventors: Michal Caspi Tal, Balyn Zaro, Irving L. Weissman, Nitya Ramadoss, William H. Robinson
  • Publication number: 20220235131
    Abstract: Methods are provided for treating a subject for an infection by a pathogen expressing a CD47-like mimic protein on its surface.
    Type: Application
    Filed: June 16, 2020
    Publication date: July 28, 2022
    Inventors: Michal Caspi Tal, Irving L. Weissman, Laughing Bear Torrez Dulgeroff, Effie Bastounis, Efthymia Matthalou, Joe Hsu, Maxim Markovic, Maia Shoham, Balyn Wood Zaro, Tal Bachar Raveh
  • Publication number: 20220120731
    Abstract: Prolonged exposure of CD8+ T cells to antigenic stimulation leads to a state of diminished function, termed exhaustion; during exhaustion there is a subset of functional CD8+ T cells defined by surface expression of SIRP(alpha) protein. On SIRP+ CD8+ T cells, expression of coinhibitmy receptors is counterbalanced by expression of co-stimulatory receptors and it is only these SIRP+ cells that actively proliferate, transcribe IFNg and show cytolytic activity. Therapeutic blockade of PD-L1 or other inhibitory receptors to reinvigorate exhausted CD8+ T cells expands the cytotoxic subset of SIRP+ CD8+ T cells.
    Type: Application
    Filed: January 30, 2020
    Publication date: April 21, 2022
    Inventors: Michal Caspi Tal, Lara Myers, Kim J. HasenKrug, Ying Ying Yiu, Irving L. Weissman
  • Publication number: 20220091104
    Abstract: Methods and kits are provided for determining whether an individual is responsive to therapeutic CD47 blockade. Specifically, the disclosure provides methods of determining whether a cell or cell population is responsive to therapeutic CD47 blockade, the method comprising: assaying a cell sample from an individual to determine (a) the level of expression of signal regulatory protein alpha (SIRPalpha) on phagocytic immune cells, or (b) the genotype of the individual at a nucleotide polymorphism (SNP) associated with SIRPalpha expression. Further disclosed are SNPs associated with SIRPalpha expression.
    Type: Application
    Filed: September 11, 2019
    Publication date: March 24, 2022
    Inventors: Ying Ying Yiu, Michal Caspi Tal, Amira Barkal, Hanna Maria Ollila, Irving L. Weissman
  • Publication number: 20220034880
    Abstract: Compositions and methods are provided for diagnosis of infections. The patterns of antibody isotype, subtype and glycosylation provide for a signature pattern that can identify infective agents and patient response to infection. Patients likely to benefit from therapeutic intervention can be discriminated from patients that have a low probability of responsiveness. Therapies are also provided.
    Type: Application
    Filed: October 1, 2019
    Publication date: February 3, 2022
    Inventors: Irving L. Weissman, Michal Caspi Tal